Herpes Zoster (Shingles) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Herpes Zoster (Shingles) – Pipeline Review, H1 2017’, provides an overview of the Herpes Zoster (Shingles) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)

– The report reviews pipeline therapeutics for Herpes Zoster (Shingles) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Herpes Zoster (Shingles) therapeutics and enlists all their major and minor projects

– The report assesses Herpes Zoster (Shingles) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

Beijing Minhai Biotechnology Co Ltd

ContraVir Pharmaceuticals Inc

Epiphany Biosciences Inc

Foamix Pharmaceuticals Ltd

GeneOne Life Science Inc

GlaxoSmithKline Plc

Merck & Co Inc

NAL Pharmaceuticals Ltd

NanoViricides Inc

SK Chemicals Co Ltd

TSRL Inc

XBiotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Herpes Zoster (Shingles) - Overview

Herpes Zoster (Shingles) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Herpes Zoster (Shingles) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Beijing Minhai Biotechnology Co Ltd

ContraVir Pharmaceuticals Inc

Epiphany Biosciences Inc

Foamix Pharmaceuticals Ltd

GeneOne Life Science Inc

GlaxoSmithKline Plc

Merck & Co Inc

NAL Pharmaceuticals Ltd

NanoViricides Inc

SK Chemicals Co Ltd

TSRL Inc

XBiotech Inc

Herpes Zoster (Shingles) - Drug Profiles

acyclovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amenamevir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FV-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLS-5100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-1437173A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes zoster vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Shingles - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAL-3223 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-608 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Shingles - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-087 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

V-212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valomaciclovir stearate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Herpes Zoster (Shingles) - Dormant Projects

Herpes Zoster (Shingles) - Discontinued Products

Herpes Zoster (Shingles) - Product Development Milestones

Featured News & Press Releases

Apr 18, 2017: GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles

Feb 24, 2017: In First Phase 3 Trial, Merck's Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects

Nov 25, 2016: GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada

Oct 27, 2016: GSK presents new data for shingles candidate vaccine at IDWeek scientific conference

Oct 24, 2016: GSK announces US regulatory submission of candidate vaccine for prevention of shingles

Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM

Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles

Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug

Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study

Oct 27, 2015: GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over

Sep 08, 2015: Clinical trial for Cardiff’s shingles treatment

Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain

Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial

Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of

97.2% which does not diminish in the age groups studied

Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Herpes Zoster (Shingles), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Herpes Zoster (Shingles) – Pipeline by Astellas Pharma Inc, H1 2017

Herpes Zoster (Shingles) – Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Herpes Zoster (Shingles) – Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Herpes Zoster (Shingles) – Pipeline by Epiphany Biosciences Inc, H1 2017

Herpes Zoster (Shingles) – Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Herpes Zoster (Shingles) – Pipeline by GeneOne Life Science Inc, H1 2017

Herpes Zoster (Shingles) – Pipeline by GlaxoSmithKline Plc, H1 2017

Herpes Zoster (Shingles) – Pipeline by Merck & Co Inc, H1 2017

Herpes Zoster (Shingles) – Pipeline by NAL Pharmaceuticals Ltd, H1 2017

Herpes Zoster (Shingles) – Pipeline by NanoViricides Inc, H1 2017

Herpes Zoster (Shingles) – Pipeline by SK Chemicals Co Ltd, H1 2017

Herpes Zoster (Shingles) – Pipeline by TSRL Inc, H1 2017

Herpes Zoster (Shingles) – Pipeline by XBiotech Inc, H1 2017

Herpes Zoster (Shingles) – Dormant Projects, H1 2017

Herpes Zoster (Shingles) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Herpes Zoster (Shingles), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports